Hybio Pharmaceutical (300199) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

300199 Hybio Pharmaceutical

Watchlist

12.82
-0.59-4.40%

Post Market Dec 13 15:00 CST

11.32BMarket Cap-30.74P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Hybio Pharmaceutical (SZSE:300199) Is Carrying A Fair Bit Of Debt
Simply Wall St18:36 ET
Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online
The market has broad prospects
Gelonghui FinanceNov 17 01:35 ET
Investors Push Hybio Pharmaceutical (SZSE:300199) 4.1% Lower This Week, Company's Increasing Losses Might Be to Blame
Simply Wall StNov 4 21:25 ET
hybio pharmaceutical (300199.SZ): On October 30th, Liraglutide injection ushered in a large-scale shipment with a total value of 0.103 billion yuan.
Gelonghui November 4th丨hybio pharmaceutical (300199.SZ) stated on the investor interaction platform that on October 30th, the company's Lirarutide Injection received a large-scale delivery, with a total value of 0.103 billion yuan, which was a commercial batch order announced by the company on November 3, 2023. In the future, the company will maintain a long-term exclusive cooperation relationship with Hikma according to the agreement, continue to advance subsequent order deliveries based on the sales market demand in the USA, and receive double-digit sales profit sharing. In addition to this order, the company will gradually issue subsequent orders based on the project progress. Please stay tuned for future order fulfillment.
Gelonghui FinanceNov 4 03:17 ET
Hanyu Pharmaceutical: Report for the third quarter of 2024
SZSIOct 29 12:00 ET · Announcements
Hybio Pharmaceutical Gets China Approval for Type 2 Diabetes Injection
MT NewswiresOct 15 07:55 ET

Comments

Moomoo AI

Mar 16 21:00

Despite Hybio Pharmaceutical's share price surge, its high P/S ratio and declining medium-term revenue could risk shareholders' investments. If the P/S aligns with recent negative growth rates, investors may face disappointment.

Subdued Growth No Barrier To Hybio Pharmaceutical Co., Ltd. (SZSE:300199) With Shares Advancing 28%

Moomoo AI

Mar 6 20:25

The company's balance sheet is not considered strong due to its high debt and liabilities, coupled with a decrease in revenue and a loss before interest and tax. The company is considered risky due to these factors.

Hybio Pharmaceutical (SZSE:300199) Is Making Moderate Use Of Debt

Moomoo AI

Jan 31 19:43

Despite Hybio Pharmaceutical's recent poor growth, its high P/S ratio indicates investor optimism for a business turnaround. However, with medium-term revenue decline and expected industry growth of 35%, these prices may not be sustainable. Shareholders may face a tough period unless circumstances improve.

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Plunge Could Signal Some Risk

Moomoo AI

Dec 17, 2023 19:33

The company's high P/S ratio and decreasing revenues do not match, causing concerns for investors. Unless the recent medium-term conditions improve significantly, investors may find it difficult to perceive the share price as fair value.

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Popularity With Investors Is Under Threat From Overpricing

Moomoo AI

Nov 8, 2023 19:09

Hybio Pharmaceutical's falling revenue and pre-tax losses pose concerns over its debt level, implying potential threat to the company while its shares seem unaffected. It's deemed risky due to these factors.